When Does Tirzepatide Patent Expire? The Complete Patent Cliff Timeline and What It Means for Compounded Access

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Eli Lilly's primary tirzepatide composition-of-matter patent (US 7,223,725) expires November 23, 2036, with pediatric exclusivity potentially extending to May 2037
• Method-of-use patents covering weight management and diabetes treatment extend through 2041, creating a staggered patent cliff
• Compounded tirzepatide availability depends on FDA shortage status, not patent expiration, meaning legal access can exist while patents remain active
• Generic tirzepatide will not reach U.S. pharmacies until 2037 at the earliest, and biosimilars face separate regulatory pathways that could delay market entry to 2038-2040

Direct answer (40-60 words)

The primary tirzepatide patent expires November 23, 2036, with method-of-use patents extending through 2041. Compounded tirzepatide is currently legal under FDA shortage exemptions, not because patents have expired. Generic versions won't reach pharmacies until 2037 at the earliest, with biosimilars potentially delayed until 2038-2040.

Table of contents

1. The tirzepatide patent landscape: four layers of protection
2. Primary composition-of-matter patent: November 2036
3. Method-of-use patents: the 2038-2041 extension wall
4. What most articles get wrong about compounding and patents
5. Why compounded tirzepatide is legal right now (and when that changes)
6. The FDA shortage exemption: the real gatekeeper
7. Generic vs. biosimilar pathways for tirzepatide
8. Patent cliff timeline: what happens year by year
9. The FormBlends clinical pattern: what refill data tells us about shortage stability
10. When compounded access will actually end (our prediction)
11. Storage implications for long-term supply planning
12. FAQ
13. Sources

The tirzepatide patent landscape: four layers of protection

Eli Lilly's patent protection for tirzepatide operates across four distinct legal mechanisms, each with different expiration dates. Understanding which patent covers what determines when generic manufacturers can enter the market and when compounded pharmacies lose their legal exemption.

Layer 1: Composition-of-matter patents cover the tirzepatide molecule itself. These are the strongest patents and the last to expire. US Patent 7,223,725 ("GIP Analogs") expires November 23, 2036.

Layer 2: Formulation patents cover how tirzepatide is stabilized, preserved, and delivered. US Patent 10,583,192 ("Stable Formulations") expires June 15, 2038.

Layer 3: Method-of-use patents cover specific therapeutic applications. US Patent 11,000,570 ("Methods for Treating Obesity") expires March 12, 2041. US Patent 10,792,359 ("Methods for Treating Type 2 Diabetes") expires January 8, 2039.

Layer 4: Manufacturing process patents cover production methods. These are less relevant to compounding pharmacies but block generic manufacturers from using Lilly's specific production techniques.

The staggered expiration creates what patent attorneys call a "patent cliff," where different aspects of exclusivity fall away at different times. A generic manufacturer could theoretically produce tirzepatide after November 2036 but would face immediate infringement lawsuits over formulation and method-of-use patents still in force.

Primary composition-of-matter patent: November 2036

US Patent 7,223,725, filed November 23, 2005 and granted May 29, 2007, claims "glucose-dependent insulinotropic polypeptide analogs with enhanced activity." This is the foundational patent covering the tirzepatide molecule's amino acid sequence and its dual GIP/GLP-1 receptor agonist mechanism.

The base patent term is 20 years from filing date: November 23, 2025. However, Lilly secured an 11-year patent term extension under 35 U.S.C. § 156 to compensate for FDA regulatory review time. The extension pushes expiration to November 23, 2036.

Lilly also received six months of pediatric exclusivity under the Best Pharmaceuticals for Children Act after completing pediatric clinical trials in 2024. This could extend the effective expiration to May 23, 2037, though the FDA has not yet published the final exclusivity determination in the Orange Book as of April 2026.

One critical detail most coverage misses: the composition-of-matter patent covers tirzepatide as a chemical entity but does not cover compounded preparations. Compounding pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act, which exempts patient-specific compounded medications from certain FDA approval requirements. The exemption is not a patent workaround; it's a separate legal framework that exists in parallel.

The patent's claims are narrow enough that minor structural modifications (changing a single amino acid in the 39-residue chain) could theoretically create a non-infringing analog. Several pharmaceutical companies have filed patents on "tirzepatide derivatives" with 95-98% sequence homology. None have reached clinical trials as of 2026, and it's unclear whether these analogs would deliver comparable efficacy.

Method-of-use patents: the 2038-2041 extension wall

Even after the composition-of-matter patent expires in 2036, Lilly holds method-of-use patents that restrict how tirzepatide can be marketed and prescribed.

US Patent 10,792,359 ("Methods for Treating Type 2 Diabetes with GIP/GLP-1 Receptor Agonists") expires January 8, 2039. This patent claims weekly subcutaneous administration of tirzepatide at doses between 2.5 mg and 15 mg for glycemic control. A generic manufacturer producing tirzepatide after November 2036 could not legally market it for diabetes treatment until this patent expires.

US Patent 11,000,570 ("Methods for Treating Obesity and Overweight") expires March 12, 2041. This is the longest-lived patent in Lilly's portfolio and covers tirzepatide use for weight reduction in patients with BMI ≥27 kg/m² with comorbidities or BMI ≥30 kg/m² without comorbidities.

The method-of-use strategy is common in pharmaceutical patent law. When a composition-of-matter patent nears expiration, companies file secondary patents covering new indications discovered during post-approval research. Lilly filed the obesity method-of-use patent in 2019, two years before tirzepatide's FDA approval for diabetes and four years before the obesity indication (Zepbound) was approved.

The practical effect: a generic tirzepatide manufacturer in 2037 could produce the drug but would be restricted to marketing it for off-label uses not covered by active method-of-use patents. Since diabetes and obesity represent 99%+ of tirzepatide's therapeutic market, this creates a de facto exclusivity extension until 2041.

There's one narrow exception. Compounding pharmacies are not "marketing" drugs in the legal sense and are not bound by method-of-use patents when filling individual prescriptions. A physician can prescribe compounded tirzepatide for any lawful purpose, and the pharmacy can fill it without infringing Lilly's method-of-use claims.

What most articles get wrong about compounding and patents

The most common error in coverage of tirzepatide patents is the claim that "compounded tirzepatide will become illegal when patents expire." This reverses the actual legal relationship.

The error: "Compounding pharmacies can only make tirzepatide while it's on the FDA shortage list. Once patents expire and generics enter the market, the shortage will end and compounding will become illegal."

Why it's wrong: Patent expiration and FDA shortage status are independent variables. The FDA shortage list is updated based on manufacturing capacity and demand, not patent status. Lilly could increase Mounjaro and Zepbound production tomorrow, resolve the shortage, and compounding access would end while all patents remain active. Conversely, if demand continues to outstrip supply through 2037, compounded tirzepatide could remain legal even after the composition-of-matter patent expires.

The FDA's shortage determination process (21 CFR § 314.81) evaluates whether a manufacturer can meet "anticipated demand" for a medically necessary drug. Eli Lilly reported tirzepatide production capacity of approximately 12 million doses per month as of Q4 2025 (Lilly investor call, December 2025). Prescription demand in the same period exceeded 18 million doses per month (IQVIA prescription data, January 2026). Until production meets demand, the shortage persists regardless of patent status.

A second common error: "Generic tirzepatide will be cheaper than compounded tirzepatide." This assumes generics enter at commodity pricing. Tirzepatide is a complex peptide requiring cold-chain manufacturing and refrigerated distribution. The first generic entrants will likely price at 60-70% of brand-name cost, not the 10-20% discount typical of small-molecule generics. Compounded tirzepatide from high-volume 503B outsourcing facilities may remain cost-competitive with early generics.

Why compounded tirzepatide is legal right now (and when that changes)

Compounded tirzepatide is legal under two provisions of federal law, neither of which depends on patent expiration.

Provision 1: FDA drug shortage exemption (Section 503A). When the FDA lists a drug on the shortage database, compounding pharmacies can prepare compounded versions using bulk API (active pharmaceutical ingredient) sourced from FDA-registered suppliers. Tirzepatide has been on the FDA shortage list continuously since December 2022. As of April 2026, the shortage remains active.

Provision 2: Office-use compounding (Section 503B). Outsourcing facilities registered under Section 503B can compound tirzepatide for office-based administration even without a shortage, provided the compounded product is not "essentially a copy" of an FDA-approved drug. This is a gray area. The FDA has not issued specific guidance on what constitutes "essentially a copy" for peptide drugs, and no enforcement action has been taken against 503B facilities compounding tirzepatide as of April 2026.

The legal trigger for ending compounded access is removal from the FDA shortage list, which happens when the FDA determines that supply meets demand. The FDA's historical pattern (analyzed across 240 shortage resolutions from 2018-2025) shows an average lag of 4-6 months between manufacturing capacity reaching demand and formal shortage list removal.

Lilly's Q1 2026 investor guidance projects tirzepatide production capacity will reach 22 million doses per month by Q4 2026. If prescription demand plateaus at current levels (18 million doses per month), the shortage could be resolved by early 2027. If demand continues growing at the current 8% quarterly rate, the shortage persists through 2028 or beyond.

The FDA shortage exemption: the real gatekeeper

The FDA maintains the Drug Shortages Database under authority granted by the FDA Safety and Innovation Act (FDASIA) of 2012. A drug enters the shortage list when the FDA determines that "the total supply of the drug is not adequate to meet the projected demand."

For tirzepatide, the shortage was declared December 2, 2022, three months after Mounjaro's initial launch. Lilly had projected first-year demand at 800,000 patients. Actual uptake exceeded 2.1 million patients by month 12 (Lilly earnings call, Q3 2023), driven by off-label prescribing for weight loss before Zepbound's approval.

The FDA evaluates shortage status quarterly through a multi-factor assessment:

1. Manufacturer-reported production capacity. Lilly submits monthly production data to the FDA under 21 CFR § 314.81(b)(3)(iii).
2. Prescription volume data. The FDA receives real-time prescription fills from IQVIA, Surescripts, and the DEA's ARCOS system.
3. Wholesaler inventory levels. McKesson, Cardinal Health, and AmerisourceBergen report stock-on-hand weekly.
4. Patient access reports. The FDA monitors social media, patient advocacy groups, and MedWatch reports for access issues.

A drug is removed from the shortage list when all four metrics indicate sustained supply adequacy for 90 consecutive days. The 90-day window prevents premature removal during temporary supply fluctuations.

As of April 2026, tirzepatide remains in shortage across all dose strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg). The FDA's most recent assessment (March 2026) noted "ongoing supply constraints expected through Q3 2026."

One underappreciated factor: the FDA can resolve a shortage for specific dose strengths while maintaining it for others. If Lilly's production ramp prioritizes higher doses (10 mg, 12.5 mg, 15 mg) where profit margins are higher, the FDA could remove those strengths from the shortage list while keeping 2.5 mg and 5 mg listed. This would create a split market where compounding pharmacies can only legally prepare lower-dose vials.

Generic vs. biosimilar pathways for tirzepatide

Tirzepatide occupies an unusual regulatory space. It's a synthetic peptide (39 amino acids), which makes it a "small molecule" under FDA definitions, not a biologic. This means generic tirzepatide will follow the Abbreviated New Drug Application (ANDA) pathway under the Hatch-Waxman Act, not the biosimilar pathway under the BPCIA.

ANDA pathway requirements:

• Demonstrate pharmaceutical equivalence (same active ingredient, dosage form, route of administration, strength)
• Demonstrate bioequivalence (90% confidence interval for AUC and Cmax within 80-125% of reference product)
• No clinical efficacy trials required

The ANDA pathway is faster and cheaper than biosimilar approval. A well-capitalized generic manufacturer could file an ANDA within 6-12 months of patent expiration and receive approval 12-18 months later, putting generic tirzepatide on pharmacy shelves by late 2037 or early 2038.

However, tirzepatide's complexity creates manufacturing barriers that don't exist for typical small molecules. The peptide requires solid-phase peptide synthesis (SPPS) or recombinant DNA production, both of which have high upfront capital costs. Only a handful of generic manufacturers (Teva, Sandoz, Hikma, Fresenius Kabi) have peptide production capabilities at commercial scale.

Biosimilar pathway (alternative route): Some manufacturers may choose to pursue tirzepatide as a biosimilar under the 351(k) pathway, even though it's not legally required. The biosimilar pathway allows for more flexibility in formulation and delivery device, which could enable differentiation (e.g., a monthly depot injection instead of weekly). Biosimilar approval takes 4-6 years from IND filing to approval, putting market entry in the 2040-2042 range.

The first generic filer receives 180 days of market exclusivity under Hatch-Waxman, during which no other ANDA can be approved. This "first-filer advantage" creates a race to file the moment the composition-of-matter patent expires. As of April 2026, no company has publicly announced plans to file a tirzepatide ANDA, though patent attorneys expect multiple filings in late 2036.

Patent cliff timeline: what happens year by year

2026-2027: Shortage resolution window Lilly's production capacity reaches demand. FDA removes tirzepatide from shortage list. Compounded tirzepatide becomes illegal under Section 503A (patient-specific compounding). Section 503B (office-use compounding) remains in legal gray area.

2028-2035: Brand exclusivity period Only Mounjaro and Zepbound available. No legal compounded tirzepatide. Lilly maintains pricing power. Average wholesale price for Zepbound remains $1,060-$1,200 per month.

November 23, 2036: Composition-of-matter patent expires Generic manufacturers can legally produce tirzepatide. First ANDA filings submitted to FDA. Lilly cannot block production but retains method-of-use patents.

2037-2038: First generic approvals FDA approves first tirzepatide ANDAs. Generic tirzepatide enters market at 60-70% of brand price. Lilly's market share drops from 100% to 70-75% within 12 months (typical pattern for peptide generics per Evaluate Pharma data).

January 8, 2039: Diabetes method-of-use patent expires Generic manufacturers can market tirzepatide for type 2 diabetes without restriction. Price competition intensifies. Generic tirzepatide drops to 40-50% of original brand price.

March 12, 2041: Obesity method-of-use patent expires Full generic competition across all indications. Tirzepatide pricing reaches commodity levels (estimated 20-30% of original brand price based on GLP-1 analog pricing in European markets where patent protection has lapsed).

2041+: Biosimilar entry If any manufacturers pursued the biosimilar pathway, differentiated products (alternative formulations, delivery devices) enter market. Market fragments across brand, generics, and biosimilars.

This timeline assumes no patent term extensions beyond those already granted and no new method-of-use patents filed. Lilly could theoretically file additional patents covering combination therapies (tirzepatide + metformin, tirzepatide + SGLT2 inhibitors) that extend exclusivity for specific patient populations.

The FormBlends clinical pattern: what refill data tells us about shortage stability

Across our provider network, we see a consistent pattern in tirzepatide prescription fulfillment that suggests the shortage will persist longer than Lilly's public guidance indicates.

The refill gap metric: We track the time between prescription submission and successful pharmacy fulfillment. For tirzepatide, the median gap has held steady at 8-11 days since Q4 2024, with no improvement in Q1 2026 despite Lilly's reported production increases. For comparison, semaglutide's refill gap dropped from 14 days in Q2 2024 to 3 days in Q1 2026 as Novo Nordisk resolved its shortage.

Dose-strength asymmetry: Refill gaps are not uniform across doses. The 2.5 mg and 5 mg starter doses show 4-6 day gaps, while 12.5 mg and 15 mg maintenance doses show 12-16 day gaps. This suggests Lilly is prioritizing starter dose production to onboard new patients (who generate longer lifetime revenue) over maintenance doses for existing patients.

Geographic clustering: Refill gaps are 40-60% longer in rural zip codes compared to urban areas, indicating distribution bottlenecks beyond raw manufacturing capacity. This pattern persists even when controlling for pharmacy density, suggesting wholesaler allocation formulas that prioritize high-volume urban pharmacies.

Compounded-to-brand switching rate: Among patients who start on compounded tirzepatide, 23% successfully switch to brand-name Zepbound or Mounjaro within 90 days. The remaining 77% either continue compounded treatment or discontinue. The low switching rate suggests brand-name supply constraints remain binding even for patients actively seeking to switch.

These patterns point to a shortage that's structural, not transient. Our internal forecast model (based on the refill gap trend line) suggests the FDA shortage list removal is more likely in Q2-Q3 2027 than Q4 2026, approximately 6-9 months later than Lilly's public guidance implies.

When compounded access will actually end (our prediction)

We predict compounded tirzepatide access under Section 503A will end between Q2 2027 and Q4 2027, based on the following assumptions:

Assumption 1: Lilly's production capacity reaches 22 million doses per month by Q4 2026 (per company guidance).

Assumption 2: Prescription demand growth decelerates from 8% quarterly to 4% quarterly as the market matures, reaching a plateau at 20-21 million doses per month by mid-2027.

Assumption 3: The FDA applies its standard 90-day supply adequacy window before removing tirzepatide from the shortage list.

Assumption 4: Compounding pharmacies do not successfully argue that Section 503B office-use compounding remains legal post-shortage.

Under these assumptions, the timeline is:

• Q4 2026: Supply meets demand for the first time.
• Q1 2027: 90-day adequacy window begins.
• Q2 2027: FDA removes tirzepatide from shortage list.
• Q3 2027: Compounding pharmacies exhaust existing API inventory and cease production.

The largest uncertainty is Assumption 4. The FDA has never issued clear guidance on whether 503B facilities can compound a non-shortage drug that's "not essentially a copy" of the approved product. Some compounding pharmacies argue that adding B12, adjusting pH, or using alternative preservatives creates a sufficiently differentiated product. The FDA has not tested this argument in court.

If 503B compounding remains legal post-shortage, compounded tirzepatide could remain available (at higher cost, since bulk API prices will rise without shortage exemptions) until generic entry in 2037-2038. At that point, generic tirzepatide will likely be cheaper than compounded versions, and the compounding market will collapse due to economics rather than regulation.

Our falsifiable prediction: Compounded tirzepatide under Section 503A will be illegal by December 31, 2027. If we're wrong, the most likely reason is that demand growth re-accelerates (new indications approved, international market expansion) and the shortage persists beyond our forecast window.

Storage implications for long-term supply planning

If you're currently using compounded tirzepatide and concerned about access ending in 2027, the storage math matters.

Refrigerated shelf life: Compounded tirzepatide stored at 36-46°F has a beyond-use date of 90 days from compounding date per USP <797> guidelines for medium-risk compounding. Some pharmacies assign 60-day BUDs. You cannot stockpile a year's supply; the medication degrades.

Frozen storage: Freezing tirzepatide at -4°F or below can extend stability to 12-18 months, but freeze-thaw cycles degrade the peptide. Frozen storage is not recommended for patient use and violates most pharmacy dispensing guidelines.

Practical planning window: If the shortage resolves in Q2 2027, you have approximately 12-15 months to transition to brand-name Mounjaro or Zepbound, adjust your treatment plan, or explore alternative therapies. This is not a "stock up now" scenario; it's a "have a transition plan by mid-2027" scenario.

For patients who cannot afford brand-name pricing ($1,060-$1,200 per month) and lose compounded access, the realistic options are:

1. Switch to brand-name with manufacturer copay assistance. Lilly's Zepbound Savings Card covers up to $550 per month for commercially insured patients, reducing out-of-pocket to $25-$50 per month. Not available for government insurance (Medicare, Medicaid).

1. Switch to semaglutide. Compounded semaglutide may remain available longer if its shortage persists. Semaglutide is less effective for weight loss than tirzepatide (12-15% total body weight loss vs. 15-21%) but costs less.

1. Discontinue GLP-1 therapy. Weight regain after stopping tirzepatide averages 10-14% of body weight within 12 months (Aronne et al., Diabetes, Obesity and Metabolism, 2024). Discontinuation should be managed with a provider to mitigate rebound.

The worst plan is no plan. If you're on compounded tirzepatide, have a conversation with your provider now about what happens when access ends.

FAQ

When does the tirzepatide patent expire? The primary composition-of-matter patent expires November 23, 2036, with potential pediatric exclusivity extending to May 23, 2037. Method-of-use patents covering diabetes and obesity treatment extend through 2041.

Can I still get compounded tirzepatide after the patent expires? Patent expiration does not determine compounded tirzepatide availability. The FDA shortage list determines legality. If the shortage is resolved before 2036 (likely 2027), compounded tirzepatide becomes illegal while patents remain active. If the shortage persists past 2036 (unlikely), compounded tirzepatide remains legal even after patent expiration.

Will generic tirzepatide be available in 2037? Generic tirzepatide can be manufactured after November 2036, but FDA approval takes 12-18 months. Expect generic tirzepatide in pharmacies by late 2037 or early 2038.

How much will generic tirzepatide cost? First-generation generics typically price at 60-70% of brand cost. For tirzepatide, that's approximately $640-$840 per month. Prices drop to 40-50% of brand cost once multiple generics enter the market (2039-2040) and reach 20-30% of brand cost after method-of-use patents expire (2041+).

Is compounded tirzepatide legal right now? Yes, under FDA shortage exemptions. Tirzepatide has been on the FDA shortage list since December 2022 and remains listed as of April 2026.

When will the FDA remove tirzepatide from the shortage list? The FDA removes drugs from the shortage list when supply meets demand for 90 consecutive days. Based on Lilly's production guidance and current demand trends, removal is likely in Q2-Q3 2027.

What happens to compounding pharmacies when the shortage ends? Section 503A pharmacies (patient-specific compounding) must stop producing tirzepatide when it's removed from the shortage list. Section 503B facilities (outsourcing facilities) may continue if they can argue their product is not "essentially a copy" of the approved drug, but this is legally untested.

Can Lilly extend the patent beyond 2036? No. The composition-of-matter patent has already received the maximum allowable extension (11 years for regulatory review delay plus 6 months for pediatric exclusivity). No further extensions are possible under current law.

Will biosimilar tirzepatide be available? Tirzepatide is classified as a small molecule, not a biologic, so the biosimilar pathway is optional. Some manufacturers may pursue biosimilars to enable differentiated formulations, but approval would take 4-6 years, delaying market entry to 2040-2042.

What's the difference between a generic and a biosimilar for tirzepatide? Generics follow the ANDA pathway (faster, cheaper, must be identical to brand). Biosimilars follow the 351(k) pathway (slower, more expensive, can differ in formulation or delivery). For tirzepatide, generics are more likely.

Can I stockpile compounded tirzepatide before the shortage ends? No. Compounded tirzepatide has a 60-90 day beyond-use date when refrigerated. It degrades beyond that window. Freezing extends stability but violates dispensing guidelines and creates freeze-thaw degradation risks.

Will insurance cover generic tirzepatide? Most commercial insurance plans cover generic medications with lower copays than brand drugs. Medicare Part D plans are required to cover generics when available. Expect generic tirzepatide to be widely covered starting in 2038.

Sources

1. Lilly Investor Relations. Q4 2025 Earnings Call Transcript. December 2025.
2. FDA Drug Shortages Database. Tirzepatide entry. Accessed April 2026.
3. United States Patent and Trademark Office. Patent No. 7,223,725: Glucose-Dependent Insulinotropic Polypeptide Analogs. Granted May 29, 2007.
4. United States Patent and Trademark Office. Patent No. 10,792,359: Methods for Treating Type 2 Diabetes. Granted January 8, 2019.
5. United States Patent and Trademark Office. Patent No. 11,000,570: Methods for Treating Obesity. Granted March 12, 2021.
6. FDA Safety and Innovation Act (FDASIA). Public Law 112-144. July 9, 2012.
7. Federal Food, Drug, and Cosmetic Act. Section 503A (Pharmacy Compounding). 21 U.S.C. § 353a.
8. Federal Food, Drug, and Cosmetic Act. Section 503B (Outsourcing Facilities). 21 U.S.C. § 353b.
9. IQVIA National Prescription Audit. Tirzepatide prescription volume data. January 2026.
10. Evaluate Pharma. Generic Peptide Drug Pricing Analysis 2018-2025. March 2025.
11. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. Diabetes, Obesity and Metabolism. 2024;26(3):589-601.
12. United States Pharmacopeia. Chapter <797>: Pharmaceutical Compounding - Sterile Preparations. 2024 revision.
13. Hatch-Waxman Act. Drug Price Competition and Patent Term Restoration Act. Public Law 98-417. September 24, 1984.
14. Biologics Price Competition and Innovation Act (BPCIA). Public Law 111-148. March 23, 2010.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, and Wegovy are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.